U266 Cells

The U266 cell line, also known as U-266, is a human multiple myeloma cell line that was established from the peripheral blood of a 53-year-old man with IgE myeloma. This cell line is characterized by the secretion of both light and heavy immunoglobulin chains, predominantly lambda light chains and IgE heavy chains. The U266 cell line exhibits typical B lymphocyte markers and has been used extensively in the study of myeloma biology, particularly in understanding the pathophysiological mechanisms of plasma cell malignancies and the immune response. U266 cells are valuable for their role in drug discovery and development, providing a robust model for evaluating the efficacy of anti-myeloma agents. They are also utilized in the study of myeloma cell interactions with the bone marrow microenvironment, which is crucial for understanding myeloma progression and resistance to therapy. Genetic studies have revealed several chromosomal abnormalities in U266 cells, which contribute to their malignant phenotype and resistance to apoptosis. This cell line has been instrumental in the advancement of molecular targeted therapies in multiple myeloma.